Trials / Withdrawn
WithdrawnNCT00129558
A Study to Evaluate PT-523 in Patients With Refractory Leukemia
A Phase I/II Study of PT-523 in Patients With Refractory Leukemia
- Status
- Withdrawn
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Spectrum Pharmaceuticals, Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This Phase I/II, multi-centered, non-randomized, trial is designed to determine a safe dose of PT-523 for subjects, and to make preliminary evaluations on the activity of PT-523 as therapy in subjects with refractory leukemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PT-523 for Injection |
Timeline
- Start date
- 2005-07-01
- Primary completion
- 2011-09-01
- Completion
- 2011-09-01
- First posted
- 2005-08-12
- Last updated
- 2013-12-04
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00129558. Inclusion in this directory is not an endorsement.